soberana 02 soberana 02 soberana 02 or soberana 2, technical name finlay-fr-2, is a covid-19 vaccine produced by the finlay institute, a cuban epidemiological research institute. the vaccine is known as pastocovac (persian: پاستوکووک) in iran, where it has been developed in collaboration with the pasteur institute of iran. soberana 02a vial of soberana 02vaccine descriptiontargetsars-cov-2vaccine typeconjugateclinical datatrade namespasteurother namesfinlay-fr-2pasteurcovac, pasto covac, پاستوکووکroutes ofadministrationintramuscularlegal statuslegal status full and emergency authorizations full list of soberana 02 authorizationsidentifiersdrugbankdb16524 part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal it is a conjugate vaccine that requires two doses, the second one being administered 28 days after the first shot. a third (booster) dose of soberana plus may also be given on day 56. it has received emergency use authorization in iran on june 2021, and in cuba on august 2021, where it has also been approved for children above 2 years old. the name of the vaccine, soberana, is a spanish word that means "sovereign". it followed a previous candidate vaccine called soberana-01 (finlay-fr-1). medical uses the vaccine requires two doses, the second one being administered four weeks after the first shot. a third (boost) dose of soberana plus may also be given on eight weeks. efficacy the interim results of a phase iii trial in cuba has shown an efficacy of 71.1% after only two doses, increasing to 92.4% after adding a dose of soberana plus. the trial was undertaken while the delta variant was gradually taking over from beta in havana. the interim results of the phase iii trial in iran show that the efficacy of a two-dose regimen is 51.31% against symptomatic disease, 78.35% against severe disease, and 76.78% against hospitalization. a third dose of soberana plus increases the efficacy against symptomatic disease to 70.58%, 83.52% against severe disease, and 91.76% against hospitalization. 89% of the cases in the iranian trial were identified as having the delta strain. the final results of the phase iii trials in cuba show an efficacy against symptomatic disease of 71.0% against the beta and delta strains, while a third dose of soberana plus increased the efficacy up to 92.4%. efficacy against severe disease and death is 100% for the heterologous three-dose regimen. the final results of the phase iii trial in iran show an efficacy of 67% against symptomatic disease and 96.5% against severe disease and hospitalization for a heterologous three-dose regimen. no deaths were observed in the trial group that received the three-dose regimen. unlike the phase iii trials in cuba, the majority of cases throughout the entire trial were of the delta strain (more than 90% at the time of vaccine evaluation). pharmacology finlay-fr-2 is a conjugate vaccine. it consists of the receptor binding domain of the sars-cov-2 spike protein conjugated chemically to tetanus toxoid. professor ihosvany castellanos santos said that the antigen is safe because it contains parts instead of the whole live virus, and therefore it does not require extra refrigeration, like other candidates in the world. manufacturing the spike protein subunit is produced in chinese hamster ovary cell culture. in the acs chemical biology article, scientists from cuba explain details of the vaccines technology and production. production deliveries planned production potential production production cuba iran (under name of pasteurcovac) potential production ghana argentina in cuba the cuban government says it is planning to produce 100 million doses of its vaccine to respond to its own demand and that of other countries. cuba has also suggested that, once it's approved, it will offer the vaccine to tourists visiting the country. the production of the first batch of about 100,000 doses will start in april. josé moya, representative of the world health organization and the pan american health organization (paho) in cuba, suggested that after the vaccine passes all clinical stages, it could be included as part of paho's revolving fund. the roll-out began with an "interventional trial" that consisted of inoculating 150,000 at-risk participants which seems to be defined as health-care workers. on april 11, 2021, the ministry of public health of cuba announced that 75,000 health-care workers were inoculated with their first dose of either of the two cuba's phase iii vaccines (the other being abdala). by april 2022, cuba inoculated 9.9 million of its 11.2 million residents, 6.4 million have received booster doses. the vaccine campaign using domestic products was heralded as a huge success by cuban president miguel diaz-canel when case loads were down significantly since january 2022. the soberana vaccine preparations were particularly effective in children, preventing 70,000 pediatric cases before the omicron wave hit. outside cuba vietnam, iran, venezuela, argentina, pakistan, india, the african union, jamaica, and suriname have expressed interest in purchasing the vaccine, following phase 3 results. iran has signed an agreement to manufacture the vaccine and argentina is negotiating one. additionally, the cuban government offered a "transfer of technology" to ghana and will also supply "active materials" needed to make the vaccine. while the price is currently unknown, the commercialization strategy of the vaccine will be a combination of the "impact on health" and the capability of cuba's system to financially support "the production of vaccines and drugs for the country", per the director of the finlay institute, vicente vérez. up to 27 november 2021, 8 millions doses of pasteurcovac have been produced in iran. clinical trials soberana vaccine family clinical trials registration group participants phase date id title 2020-08-13 rpcec00000332 soberana 01 two low doses finlay-fr-1 two high doses finlay-fr-1 control (va-mengoc-bc®) 676 i/ii 2020-10-17 rpcec00000338 soberana 01a two high doses finlay-fr-1 + booster finlay-fr-1 two high doses finlay-fr-1 + booster finlay-fr-1a two high doses finlay-fr-1a + booster finlay-fr-1a two low doses finlay-fr-1a + booster finlay-fr-1a 60 i 2020-10-27 rpcec00000340 soberana 02 two low doses finlay-fr-2 + booster finlay-fr-2 two high doses finlay-fr-2 + booster finlay-fr-2 two low doses finlay-fr-2 + booster finlay-fr-1a two high doses finlay-fr-2 + booster finlay-fr-1a 40 i 2020-12-17 rpcec00000347 soberana 02a two doses finlay-fr-2 (batch 1) + booster finlay-fr-2 two doses finlay-fr-2 (batch 2) + booster finlay-fr-2 two doses finlay-fr-2 (batch 1) + booster finlay-fr-1a two doses finlay-fr-2 (batch 2) + booster finlay-fr-1a 100 iia two doses batch 1 finlay-fr-2 + booster finlay-fr-1a two doses batch 2 finlay-fr-2 + booster finlay-fr-1a placebo 810 iib 2021-01-05 rpcec00000349 soberana 01b 1-dose finlay-fr-1a 30 i 2021-03-03 rpcec00000354 soberana 02-faseiii two doses finlay-fr-2 two doses finlay-fr-2 + booster finlay-fr-1a placebo 44,010 iii 2021-03-19 rpcec00000360 soberana - intervention two doses finlay-fr-2 + booster finlay-fr-1a 150,000 2021-04-09 rpcec00000366 soberana plus 1-dose finlay-fr-1a 20 iia 1-dose finlay-fr-1a placebo 430 iib 2021-04-24 irct20210303050558n1 phase iii in iran two doses soberana 02 two doses soberana 02 + booster soberana plus placebo 24,000 iii 2021-06-10 rpcec00000374 soberana pediatria two doses finlay-fr-2 + booster finlay-fr-1a 350 i/ii phase i finlay-fr-2, which started being developed in october 2020, had 40 volunteers for its phase i, according to the cuban public registry of clinical trials, with an open, sequential and adaptive study to assess safety, reactogenicity and explore immunogenicity of the vaccine. phase ii phase iia involved 100 cubans, and phase iib of the vaccine will have 900 volunteers between 19 and 80 years. vicente vérez, director general of the finlay vaccine institute, said that the vaccine has shown to give an immune response after 14 days. the second phase has been supervised by iranian officials from the pasteur institute. phase iii a vial of soberana 02 vaccine in iran for use in the phase iii clinical trials a woman getting vaccinated as part of phase iii trials phase iii commenced at the beginning of march as originally scheduled, and "ready to publish" results are expected by june. the trial volunteers are divided into three groups: some will receive two doses of the vaccine 28 days apart, another group will get two doses plus a third immune booster (soberana plus), and the third a placebo. although the trials involve thousands of adult volunteers recruited in havana, cuba's public health officials have said that they will also need to conduct phase iii trials abroad because the island doesn't have an outbreak of sufficient scale to produce meaningful statistics on vaccine protection. on march 13, 2021, the cuban biotechnology and pharmaceutical industries business group (biocubafarma) announced on social media that it had sent 100,000 doses of its soberana 02 coronavirus vaccine candidate to the pasteur institute of iran for clinical testing, “as part of the collaboration with other countries in the development of covid-19 vaccines.” on april 26, 2021, it was reported that a phase iii conducted by the pasteur institute of iran was approved to be started in iran it was previously reported that the institute will host phase 3, but the pre-requisites were "technology transfer and joint production". the phase iii trial in iran has been conducted on 24,000 adults, aged between 18 and 80 years old in 8 cities. the interim results of the phase iii trial in iran show that the efficacy of a two-dose regimen is 51.31% against symptomatic disease, 78.35% against severe disease, and 76.78% against hospitalization. a third dose of soberana plus increases the efficacy against symptomatic disease to 70.58%, 83.52% against severe disease, and 91.76% against hospitalization. the study was conducted when the delta variant was predominant in the country, with 89% of the cases in the iranian trial identified as having the delta strain. given the limited number of reported deaths in the trial, it was virtually impossible to analyze efficacy against death for both the two and three dose regimens. mexico plans to host a phase 3 trial. the final results of the phase iii trials in cuba show an efficacy against symptomatic disease of 71.0% against the beta and delta strains, while a third dose of soberana plus increased the efficacy up to 92.4%. efficacy against severe disease and death is 100% for the heterologous three-dose regimen. the final results of the phase iii trial in iran show an efficacy of 67% against symptomatic disease and 96.5% against severe disease and hospitalization for a heterologous three-dose regimen. no deaths were observed